Meeting
2022 ASCO Quality Care Symposium
Financial toxicity of front-line platinum etoposide plus atezolizumab versus durvalumab in extensive-stage small-cell (ES-SCLC) lung cancer.
Authors
Bradley Harrison
Atrium Health, Charlotte, NC
Bradley Harrison, Nicole Keith, Allison Verbyla, Kathryn Finch Mileham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience
Sub Track
Cost and Cost-Effectiveness of Care
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 23)
DOI
10.1200/JCO.2022.40.28_suppl.023
Abstract #
23
Poster Bd #
A21
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC).
First Author: Solange Peters
Poster
2023 ASCO Annual Meeting
Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.
First Author: Aditya Juloori
Poster
2024 ASCO Annual Meeting
Survival outcomes of patients with extensive-stage small cell lung cancer who received treatment with atezolizumab in combination with carboplatin and etoposide: A propensity score adjusted cohort study.
First Author: Heya Batah
First Author: Jeddeo Paul